3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid has been researched along with Coronary Heart Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bitterman, H; Lefer, AM; Lefer, DJ | 1 |
| Kitzen, JM; Lucchesi, BR; Lynch, JJ; Uprichard, AC; Venkatesh, N | 1 |
| Hock, CE; Lefer, AM | 1 |
3 other study(ies) available for 3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid and Coronary Heart Disease
| Article | Year |
|---|---|
Additive beneficial effects of two inhibitors of vasoconstrictor mediators in acute myocardial ischemia.
Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Heart Rate; Male; Myocardial Infarction; Myocardium; Pyridines; Rats; Rats, Inbred Strains; Thromboxane-A Synthase; Vasoconstriction | 1987 |
Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Topics: Animals; Coronary Disease; Coronary Thrombosis; Death, Sudden; Dogs; Electric Stimulation; Electrodes, Implanted; Electrophysiology; Female; Heart Rate; In Vitro Techniques; Male; Myocardial Infarction; Platelet Aggregation; Pyridines; Tachycardia; Thromboxane B2; Thromboxane-A Synthase; Ventricular Fibrillation | 1988 |
CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
Topics: Animals; Coronary Disease; Coronary Vessels; Creatine Kinase; Male; Myocardial Infarction; Myocardium; Pyridines; Rats; Rats, Inbred Strains; Thromboxane-A Synthase | 1986 |